Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Jean-Michel Molina, Anthony Lamarca, Jaime Andrade-Villanueva, Bonaventura Clotet, Nathan Clumeck, Ya-Pei Liu, Lijie Zhong, Nicolas Margot, Andrew K Cheng, Steven L Chuck, Study 145 Team, Clifford Leen

Research output: Contribution to journalArticlepeer-review

Abstract

Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 integrase inhibitor, in patients in whom previous antiretroviral treatment failed.
Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalThe Lancet Infectious Diseases
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2012

Keywords

  • Adult
  • Alanine Transaminase
  • Anti-Retroviral Agents
  • Aspartate Aminotransferases
  • CD4 Lymphocyte Count
  • Diarrhea
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • HIV Infections
  • HIV Integrase Inhibitors
  • HIV Protease Inhibitors
  • HIV-1
  • Humans
  • Lopinavir
  • Male
  • Middle Aged
  • Oligopeptides
  • Pyridines
  • Pyrrolidinones
  • Quinolones
  • RNA, Viral
  • Ritonavir
  • Treatment Outcome
  • Viral Load

Fingerprint Dive into the research topics of 'Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study'. Together they form a unique fingerprint.

Cite this